These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 10325833)
21. Biocompatibility reflected by haemostasis variables during cardiopulmonary bypass using heparin-coated circuits. Borowiec J; Bagge L; Saldeen T; Thelin S Thorac Cardiovasc Surg; 1997 Aug; 45(4):163-7. PubMed ID: 9323816 [TBL] [Abstract][Full Text] [Related]
22. Complement activation during extracorporeal circulation. In vitro comparison of Duraflo II heparin-coated and uncoated oxygenator circuits. Svennevig JL; Geiran OR; Karlsen H; Pedersen T; Mollnes TE; Kongsgard U; Frøysaker T J Thorac Cardiovasc Surg; 1993 Sep; 106(3):466-72. PubMed ID: 8361189 [TBL] [Abstract][Full Text] [Related]
23. An ex vivo evaluation of blood coagulation and thromboresistance of two extracorporeal circuit coatings with reduced and full heparin dose. Teligui L; Dalmayrac E; Mabilleau G; Macchi L; Godon A; Corbeau JJ; Denommé AS; Bouquet E; Boer C; Baufreton C Interact Cardiovasc Thorac Surg; 2014 Jun; 18(6):763-9. PubMed ID: 24632424 [TBL] [Abstract][Full Text] [Related]
24. Biocompatibility of heparin-coated cardiopulmonary bypass circuits in coronary patients with left ventricular dysfunction is superior to PMEA-coated circuits. Kutay V; Noyan T; Ozcan S; Melek Y; Ekim H; Yakut C J Card Surg; 2006; 21(6):572-7. PubMed ID: 17073955 [TBL] [Abstract][Full Text] [Related]
25. Deleterious effects of cardiopulmonary bypass on early graft function after single lung allotransplantation: evaluation of a heparin-coated bypass circuit. Francalancia NA; Aeba R; Yousem SA; Griffith BP; Marrone GC J Heart Lung Transplant; 1994; 13(3):498-507. PubMed ID: 8061027 [TBL] [Abstract][Full Text] [Related]
26. Sequestration of propofol in an extracorporeal circuit. Tarr TJ; Kent AP J Cardiothorac Anesth; 1989 Oct; 3(5 Suppl 1):75. PubMed ID: 2521009 [No Abstract] [Full Text] [Related]
27. Modified surface coatings and their effect on drug adsorption within the extracorporeal life support circuit. Preston TJ; Ratliff TM; Gomez D; Olshove VE; Nicol KK; Sargel CL; Chicoine LG J Extra Corpor Technol; 2010 Sep; 42(3):199-202. PubMed ID: 21114222 [TBL] [Abstract][Full Text] [Related]
28. Clinical study of biocompatibility between open and closed heparin-coated cardiopulmonary bypass circuits. Tanaka H; Oshiyama T; Narisawa T; Mori T; Masuda M; Kishi D; Kitou T; Miyazima S J Artif Organs; 2003; 6(4):245-52. PubMed ID: 14691666 [TBL] [Abstract][Full Text] [Related]
38. Heparin coating of extracorporeal circuits inhibits cytokine release from mononuclear cells during cardiac operations. Giomarelli P; Naldini A; Biagioli B; Borrelli E Int J Artif Organs; 2000 Apr; 23(4):250-5. PubMed ID: 10832659 [TBL] [Abstract][Full Text] [Related]
39. Thrombogenicity is not reduced when heparin and phospholipid bonded circuits are used in a rabbit model of extracorporeal circulation. Meinhardt JP; Annich GM; Miskulin J; Kawai T; Ashton BA; Bartlett RH ASAIO J; 2003; 49(4):395-400. PubMed ID: 12918580 [TBL] [Abstract][Full Text] [Related]